A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of HEC113995 PA•H2O Tablets in Healthy Subjects
Latest Information Update: 30 Oct 2020
At a glance
- Drugs HEC30654-AcOH (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Sunshine Lake Pharma
- 23 Oct 2020 New trial record